Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program

Neuropathology

Volumn 35, Issue 4, 2015, Pages 354-389

  Beach, Thomas G ^a   Adler, Charles H ^b   Sue, Lucia I ^a   Serrano, Geidy ^a   Shill, Holly A ^a   Walker, Douglas G ^a   Lue, Lihfen ^a   Roher, Alex E ^a   Dugger, Brittany N ^a   Maarouf, Chera ^a   Birdsill, Alex C ^a   Intorcia, Anthony ^a   Saxon Labelle, Megan ^a   Pullen, Joel ^a   Scroggins, Alexander ^a   Filon, Jessica ^a   Scott, Sarah ^a   Hoffman, Brittany ^a   Garcia, Angelica ^a   Caviness, John N ^b   Hentz, Joseph G ^b   Driver Dunckley, Erika ^b   Jacobson, Sandra A ^a   Davis, Kathryn J ^a   Belden, Christine M ^a   Long, Kathy E ^a   Malek Ahmadi, Michael ^a   Powell, Jessica J ^a   Gale, Lisa D ^a   Nicholson, Lisa R ^a   Caselli, Richard J ^b   Woodruff, Bryan K ^b   Rapscak, Steven Z ^c   Ahern, Geoffrey L ^c   Shi, Jiong ^d   Burke, Anna D ^e   Reiman, Eric M ^e   Sabbagh, Marwan N ^a   more..

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d BARROW NEUROLOGICAL INSTITUTE   (United States)

^e BANNER ALZHEIMER S INSTITUTE   (United States)

Author keywords

Aging; Alzheimer's disease; Autopsy; Biobank; Biospecimen; Brain bank; Cancer; Freeze thaw; Parkinson's disease; Pathology; Post mortem interval; RNA

Indexed keywords

BIOLOGICAL MARKER;

AGING; ARIZONA; AUTOPSY; BRAIN; DEGENERATIVE DISEASE; DONOR; FEMALE; HUMAN; MALE; ORGAN PRESERVATION; PATHOLOGY; POSTMORTEM CHANGE; TISSUE BANK; TISSUE SURVIVAL; TRANSPLANTATION; VERY ELDERLY;

AGED, 80 AND OVER; AGING; ARIZONA; AUTOPSY; BIOMARKERS; BRAIN; FEMALE; HUMANS; MALE; NEURODEGENERATIVE DISEASES; ORGAN PRESERVATION; POSTMORTEM CHANGES; TISSUE AND ORGAN PROCUREMENT; TISSUE BANKS; TISSUE DONORS; TISSUE SURVIVAL;

EID: 84934441622     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/neup.12189     Document Type: Article

References (345)

1. Beach TG. Alzheimer's disease and the "Valley of Death": not enough guidance from human brain tissue? J Alzheimers Dis 2013; 33 (Suppl 1): S219-S233.
2. Peschken CA, Esdaile JM. Rheumatic diseases in North America's indigenous peoples. Semin Arthritis Rheum 1999; 28: 368-391.
3. Johanneson B, Steinsson K, Lindqvist AK etal. A comparison of genome-scans performed in multicase families with systemic lupus erythematosus from different population groups. J Autoimmun 1999; 13: 137-141.
4. Lio D, Pes GM, Carru C etal. Association between the HLA-DR alleles and longevity: a study in Sardinian population. Exp Gerontol 2003; 38: 313-317.
5. Mathews CA, Reus VI, Bejarano J etal. Genetic studies of neuropsychiatric disorders in Costa Rica: a model for the use of isolated populations. Psychiatr Genet 2004; 14: 13-23.
6. Adachi T, Inanami O, Sato A. Nitric oxide (NO) is involved in increased cerebral cortical blood flow following stimulation of the nucleus basalis of Meynert in anesthetized rats. Neurosci Lett 1992; 139: 201-204.
7. Gustavsson JP, Asberg M, Schalling D. The healthy control subject in psychiatric research: impulsiveness and volunteer bias. Acta Psychiatr Scand 1997; 96: 325-328.
8. Mandel FS, Weiner M, Kaplan S, Pelcovitz D, Labruna V. An examination of bias in volunteer subject selection: findings from an in-depth child abuse study. J Trauma Stress 2000; 13: 77-88.
9. Sofuoglu M, Dudish-Poulsen S, Nicodemus KK, Babb DA, Hatsukami DK. Characteristics of research volunteers for inpatient cocaine studies: focus on selection bias. Addict Behav 2000; 25: 785-790.
10. Lim A, Kukull W, Nochlin D etal. Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. J Am Geriatr Soc 1999; 47: 564-569.
11. Allen MJ, Powers ML, Gronowski KS, Gronowski AM. Human tissue ownership and use in research: what laboratorians and researchers should know. Clin Chem 2010; 56: 1675-1682.
12. Nelkin D, Andrews L. Do the dead have interests? Policy issues for research after life. Am J Law Med 1998; 24: 261-291.
13. Kurtz SF, Strong CWGD. The 2006 revised Uniform Anatomical Gift Act - A law to save lives. Health Lawyers News 2007; February: 44-49.
14. Spokes EG. An analysis of factors influencing measurements of dopamine, noradrenaline, glutamate decarboxylase and choline acetylase in human post-mortem brain tissue. Brain 1979; 102: 333-346.
15. Spokes EG, Koch DJ. Post-mortem stability of dopamine, glutamate decarboxylase and choline acetyltransferase in the mouse brain under conditions simulating the handling of human autopsy material. J Neurochem 1978; 31: 381-383.
16. Oka T, Tagawa K, Ito H, Okazawa H. Dynamic changes of the phosphoproteome in postmortem mouse brains. PLoS ONE 2011; 6: e21405.
17. Ludes B, Pfitzinger H, Mangin P. DNA fingerprinting from tissues after variable postmortem periods. J Forensic Sci 1993; 38: 686-690.
18. Morrison MR, Griffin WS. The isolation and in vitro translation of undegraded messenger RNAs from human postmortem brain. Anal Biochem 1981; 113: 318-324.
19. Perrett CW, Marchbanks RM, Whatley SA. Characterisation of messenger RNA extracted post-mortem from the brains of schizophrenic, depressed and control subjects. J Neurol Neurosurg Psychiatry 1988; 51: 325-331.
20. Ravid R, Van Zwieten EJ, Swaab DF. Brain banking and the human hypothalamus - factors to match for, pitfalls and potentials. Prog Brain Res 1992; 93: 83-95.
21. Hynd MR, Lewohl JM, Scott HL, Dodd PR. Biochemical and molecular studies using human autopsy brain tissue. J Neurochem 2003; 85: 543-562.
22. Palmer AM, Lowe SL, Francis PT, Bowen DM. Are post-mortem biochemical studies of human brain worthwhile? Biochem Soc Trans 1988; 16: 472-475.
23. Leonard S, Logel J, Luthman D, Casanova M, Kirch D, Freedman R. Biological stability of mRNA isolated from human postmortem brain collections. Biol Psychiatry 1993; 33: 456-466.
24. Cummings TJ, Strum JC, Yoon LW, Szymanski MH, Hulette CM. Recovery and expression of messenger RNA from postmortem human brain tissue. Mod Pathol 2001; 14: 1157-1161.
25. Yasojima K, McGeer EG, McGeer PL. High stability of mRNAs postmortem and protocols for their assessment by RT-PCR. Brain Res Brain Res Protoc 2001; 8: 212-218.
26. Preece P, Cairns NJ. Quantifying mRNA in postmortem human brain: influence of gender, age at death, postmortem interval, brain pH, agonal state and inter-lobe mRNA variance. Brain Res Mol Brain Res 2003; 118: 60-71.
27. Preece P, Virley DJ, Costandi M etal. An optimistic view for quantifying mRNA in post-mortem human brain. Brain Res Mol Brain Res 2003; 116: 7-16.
28. Li JZ, Vawter MP, Walsh DM etal. Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions. Hum Mol Genet 2004; 13: 609-616.
29. Tomita H, Vawter MP, Walsh DM etal. Effect of agonal and postmortem factors on gene expression profile: quality control in microarray analyses of postmortem human brain. Biol Psychiatry 2004; 55: 346-352.
30. Ervin JF, Heinzen EL, Cronin KD etal. Postmortem delay has minimal effect on brain RNA integrity. J Neuropathol Exp Neurol 2007; 66: 1093-1099.
31. Popova T, Mennerich D, Weith A, Quast K. Effect of RNA quality on transcript intensity levels in microarray analysis of human post-mortem brain tissues. BMC Genomics 2008; 9: 91.
32. Durrenberger PF, Fernando S, Kashefi SN etal. Effects of antemortem and postmortem variables on human brain mRNA quality: a BrainNet Europe study. J Neuropathol Exp Neurol 2010; 69: 70-81.
33. Sajdel-Sulkowska EM, Majocha RE, Salim M, Zain SB, Marotta CA. The postmortem Alzheimer brain is a source of structurally and functionally intact astrocytic messenger RNA. J Neurosci Methods 1988; 23: 173-179.
34. Gilmore JH, Lawler CP, Eaton AM, Mailman RB. Postmortem stability of dopamine D1 receptor mRNA and D1 receptors. Brain Res Mol Brain Res 1993; 18: 290-296.
35. Kingsbury AE, Foster OJ, Nisbet AP etal. Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res Mol Brain Res 1995; 28: 311-318.
36. Johnston NL, Cervenak J, Shore AD, Torrey EF, Yolken RH. Multivariate analysis of RNA levels from postmortem human brains as measured by three different methods of RT-PCR. Stanley Neuropathology Consortium. J Neurosci Methods 1997; 77: 83-92.
37. Mathern GW, Pretorius JK, Kornblum HI etal. Altered hippocampal kainate-receptor mRNA levels in temporal lobe epilepsy patients. Neurobiol Dis 1998; 5: 151-176.
38. Schramm M, Falkai P, Tepest R etal. Stability of RNA transcripts in post-mortem psychiatric brains. J Neural Transm 1999; 106: 329-335.
39. Miller CL, Diglisic S, Leister F, Webster M, Yolken RH. Evaluating RNA status for RT-PCR in extracts of postmortem human brain tissue. Biotechniques 2004; 36: 628-633.
40. Johnson SA, Morgan DG, Finch CE. Extensive postmortem stability of RNA from rat and human brain. J Neurosci Res 1986; 16: 267-280.
41. Lukiw WJ, Wong L, McLachlan DR. Cytoskeletal messenger RNA stability in human neocortex: studies in normal aging and in Alzheimer's disease. Int J Neurosci 1990; 55: 81-88.
42. Burke WJ, O'Malley KL, Chung HD, Harmon SK, Miller JP, Berg L. Effect of pre- and postmortem variables on specific mRNA levels in human brain. Brain Res Mol Brain Res 1991; 11: 37-41.
43. Ragsdale DS, Miledi R. Expressional potency of mRNAs encoding receptors and voltage-activated channels in the postmortem rat brain. Proc Natl Acad Sci U S A 1991; 88: 1854-1858.
44. Ross BM, Knowler JT, McCulloch J. On the stability of messenger RNA and ribosomal RNA in the brains of control human subjects and patients with Alzheimer's disease. J Neurochem 1992; 58: 1810-1819.
45. Eastwood SL, Burnet PW, McDonald B, Clinton J, Harrison PJ. Synaptophysin gene expression in human brain: a quantitative in situ hybridization and immunocytochemical study. Neuroscience 1994; 59: 881-892.
46. Pardue S, Zimmerman AL, Morrison-Bogorad M. Selective postmortem degradation of inducible heat shock protein 70 (hsp70) mRNAs in rat brain. Cell Mol Neurobiol 1994; 14: 341-357.
47. Harrison PJ, Heath PR, Eastwood SL, Burnet PW, McDonald B, Pearson RC. The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: selective mRNA vulnerability and comparison with their encoded proteins. Neurosci Lett 1995; 200: 151-154.
48. Castensson A, Emilsson L, Preece P, Jazin EE. High-resolution quantification of specific mRNA levels in human brain autopsies and biopsies. Genome Res 2000; 10: 1219-1229.
49. Bauer M, Gramlich I, Polzin S, Patzelt D. Quantification of mRNA degradation as possible indicator of postmortem interval - a pilot study. Leg Med (Tokyo) 2003; 5: 220-227.
50. Barrachina M, Castano E, Ferrer I. TaqMan PCR assay in the control of RNA normalization in human post-mortem brain tissue. Neurochem Int 2006; 49: 276-284.
51. Dumitriu A, Moser C, Hadzi TC etal. Post-mortem interval influences á-synuclein expression in Parkinson disease brain. J Park Dis 2012; doi: 10.1155/2012/614212. Epub 2012 March 13.
52. Birdsill AC, Walker DG, Lue L, Sue LI, Beach TG. Postmortem interval effect on RNA and gene expression in human brain tissue. Cell Tissue Bank 2011; 12: 311-318.
53. Broniscer A, Baker JN, Baker SJ etal. Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma. Cancer 2010; 116: 4632-4637.
54. Zheng PP, Luider TM, Pieters R etal. Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J Neuropathol Exp Neurol 2003; 62: 855-862.
55. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 2012; 71: 266-273.
56. Burgess JA, Lescuyer P, Hainard A etal. Identification of brain cell death associated proteins in human post-mortem cerebrospinal fluid. J Proteome Res 2006; 5: 1674-1681.
57. Lescuyer P, Allard L, Zimmermann-Ivol CG etal. Identification of post-mortem cerebrospinal fluid proteins as potential biomarkers of ischemia and neurodegeneration. Proteomics 2004; 4: 2234-2241.
58. Dayon L, Hainard A, Licker V etal. Relative quantification of proteins in human cerebrospinal fluids by MS/MS using 6-plex isobaric tags. Anal Chem 2008; 80: 2921-2931.
59. Finehout EJ, Franck Z, Relkin N, Lee KH. Proteomic analysis of cerebrospinal fluid changes related to postmortem interval. Clin Chem 2006; 52: 1906-1913.
60. Burgos K, Malenica I, Metpally R etal. Profiles of Extracellular miRNA in Cerebrospinal Fluid and Serum from Patients with Alzheimer's and Parkinson's Diseases Correlate with Disease Status and Features of Pathology. PLoS ONE 2014; 9: e94839.
61. Roher AE, Maarouf CL, Sue LI, Hu Y, Wilson J, Beach TG. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease. Biomarkers 2009; 14: 493-501.
62. Maarouf CL, Andacht TM, Kokjohn TA etal. Proteomic analysis of Alzheimer's disease cerebrospinal fluid from neuropathologically diagnosed subjects. Curr Alzheimer Res 2009; 6: 399-406.
63. Maarouf CL, Beach TG, Adler CH etal. Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects. Neurol Res 2012; 34: 669-676.
64. Maarouf CL, Beach TG, Adler CH etal. Quantitative appraisal of ventricular cerebrospinal fluid biomarkers in neuropathologically diagnosed Parkinson's disease cases lacking Alzheimer's disease pathology. Biomark Insights 2013; 8: 19-28.
65. Castano EM, Roher AE, Esh CL, Kokjohn TA, Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res 2006; 28: 155-163.
66. LeWitt PA, Li J, Lu M, Beach TG, Adler CH, Guo L. 3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis. Mov Disord 2013; 28: 1653-1660.
67. Simonsen AH, Bech S, Laursen I etal. Proteomic investigations of the ventriculo-lumbar gradient in human CSF. J Neurosci Methods 2010; 191: 244-248.
68. Shaw LM, Vanderstichele H, Knapik-Czajka M etal. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 2011; 121: 597-609.
69. Kuo YM, Kokjohn TA, Watson MD etal. Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism. Am J Pathol 2000; 156: 797-805.
70. Beach TG, Adler CH, Lue L etal. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 2009; 117: 613-634.
71. Little JP, Simtchouk S, Schindler SM etal. Mitochondrial transcription factor A (Tfam) is a pro-inflammatory extracellular signaling molecule recognized by brain microglia. Mol Cell Neurosci 2014; 60: 88-96.
72. Lue LF, Kuo YM, Beach T, Walker DG. Microglia activation and anti-inflammatory regulation in Alzheimer's disease. Mol Neurobiol 2010; 41: 115-128.
73. Walker DG, Lue LF. Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases. J Neurosci Res 2005; 81: 412-425.
74. Lue LF, Brachova L, Walker DG, Rogers J. Characterization of glial cultures from rapid autopsies of Alzheimer's and control patients. Neurobiol Aging 1996; 17: 421-429.
75. Lue LF, Walker DG. Modeling Alzheimer's disease immune therapy mechanisms: interactions of human postmortem microglia with antibody-opsonized amyloid beta peptide. J Neurosci Res 2002; 70: 599-610.
76. Rogers J, Lue LF, Walker DG etal. Elucidating molecular mechanisms of Alzheimer's disease in microglial cultures. Ernst Schering Res Found Workshop 2002; 39: 25-44.
77. Roher AE, Kuo YM, Esh C etal. Cortical and leptomeningeal cerebrovascular amyloid and white matter pathology in Alzheimer's disease. Mol Med 2003; 9: 112-122.
78. Vonsattel JP, Aizawa H, Ge P etal. An improved approach to prepare human brains for research. J Neuropathol Exp Neurol 1995; 54: 42-56.
79. Beach TG, Tago H, Nagai T, Kimura H, McGeer PL, McGeer EG. Perfusion-fixation of the human brain for immunohistochemistry: comparison with immersion-fixation. J Neurosci Methods 1987; 19: 183-192.
80. Leong AS, Gilham PN. The effects of progressive formaldehyde fixation on the preservation of tissue antigens. Pathology 1989; 21: 266-268.
81. Pollard K, Lunny D, Holgate CS, Jackson P, Bird CC. Fixation, processing, and immunochemical reagent effects on preservation of T-lymphocyte surface membrane antigens in paraffin-embedded tissue. J Histochem Cytochem 1987; 35: 1329-1338.
82. Beach TG, White CL, Hamilton RL etal. Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol 2008; 116: 277-288.
83. Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1991; 1: 213-216.
84. Cummings BJ. Plaques and tangles: searching for primary events in a forest of data. Neurobiol Aging 1997; 18: 358-362.
85. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991; 82: 239-259.
86. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-1800.
87. Braak H, Braak E, Bohl J, Lang W. Alzheimer's disease: amyloid plaques in the cerebellum. J Neurol Sci 1989; 93: 277-287.
88. Braak H, Braak E, Ohm T, Bohl J. Alzheimer's disease: mismatch between amyloid plaques and neuritic plaques. Neurosci Lett 1989; 103: 24-28.
89. Braak H, Braak E, Kalus P. Alzheimer's disease: areal and laminar pathology in the occipital isocortex. Acta Neuropathol 1989; 77: 494-506.
90. Braak H, Braak E. Alzheimer's disease: striatal amyloid deposits and neurofibrillary changes. J Neuropathol Exp Neurol 1990; 49: 215-224.
91. Akiyama H, Tago H, Itagaki S, McGeer PL. Occurrence of diffuse amyloid deposits in the presubicular parvopyramidal layer in Alzheimer's disease. Acta Neuropathol 1990; 79: 537-544.
92. Halliday G, Flowers D, Baum L. Analysis of staining methods for different cortical plaques in Alzheimer's disease. Acta Neuropathol 1994; 87: 174-186.
93. Rosenwald A, Reusche E, Ogomori K, Teichert HM. Comparison of silver stainings and immunohistology for the detection of neurofibrillary tangles and extracellular cerebral amyloid in paraffin sections. Acta Neuropathol 1993; 86: 182-186.
94. Vallet PG, Guntern R, Hof PR etal. A comparative study of histological and immunohistochemical methods for neurofibrillary tangles and senile plaques in Alzheimer's disease. Acta Neuropathol 1992; 83: 170-178.
95. He Y, Duyckaerts C, Delaere P, Piette F, Hauw JJ. Alzheimer's lesions labelled by anti-ubiquitin antibodies: comparison with other staining techniques. A study of 15 cases with graded intellectual status in ageing and Alzheimer's disease. Neuropathol Appl Neurobiol 1993; 19: 364-371.
96. Clark CM, Pontecorvo MJ, Beach TG etal. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol 2012; 11: 669-678.
97. Dugger BN, Clark CM, Serrano G etal. Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. J Neuropathol Exp Neurol 2014; 73: 72-80.
98. Choi SR, Schneider JA, Bennett DA etal. Correlation of amyloid PET ligand florbetapir F 18 binding with Abeta aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord 2012; 26: 8-16.
99. Kalback W, Esh C, Castano EM etal. Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol Res 2004; 26: 525-539.
100. Arai T, Ikeda K, Akiyama H etal. Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick's disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol 2001; 101: 167-173.
101. Evidente VG, Adler CH, Sabbagh MN etal. Neuropathological findings of PSP in the elderly without clinical PSP: possible incidental PSP? Parkinsonism Relat Disord 2011; 17: 365-371.
102. Arnold SJ, Dugger BN, Beach TG. TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologies. Acta Neuropathol 2013; 126: 51-57.
103. Mirra SS, Heyman A, McKeel D etal. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-486.
104. Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 1997; 56: 1095-1097.
105. Montine TJ, Phelps CH, Beach TG etal. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012; 123: 1-11.
106. McKeith IG, Dickson DW, Lowe J etal. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872.
107. West MJ. Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci 1999; 22: 51-61.
108. Gundersen HJ, Bagger P, Bendtsen TF etal. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 1988; 96: 857-881.
109. Beach TG, Adler CH, Sue LI etal. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol 2008; 115: 445-451.
110. Beach TG, Wilson JR, Sue LI etal. Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol (Berl) 2007; 113: 13-21.
111. Roher AE, Esh C etal. Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol 2003; 23: 2055-2062.
112. Roher AE, Maarouf CL, Malek-Ahmadi M etal. Subjects harboring presenilin familial Alzheimer's disease mutations exhibit diverse white matter biochemistry alterations. Am J Neurodegener Dis 2013; 2: 187-207.
113. Castano EM, Maarouf CL, Wu T etal. Alzheimer disease periventricular white matter lesions exhibit specific proteomic profile alterations. Neurochem Int 2013; 62: 145-156.
114. Dugger BN, Adler CH, Shill HA etal. Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism Relat Disord 2014; 20: 525-529.
115. Choi SA, Evidente VG, Caviness JN etal. Are there differences in cerebral white matter lesion burdens between Parkinson's disease patients with or without dementia? Acta Neuropathol 2010; 119: 147-149.
116. Roher AE, Weiss N, Kokjohn TA etal. Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 2002; 41: 11080-11090.
117. Westover MB, Bianchi MT, Yang C, Schneider JA, Greenberg SM. Estimating cerebral microinfarct burden from autopsy samples. Neurology 2013; 80: 1365-1369.
118. Nelson PT, Alafuzoff I, Bigio EH etal. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012; 71: 362-381.
119. Kovari E, Gold G, Herrmann FR etal. Cortical microinfarcts and demyelination significantly affect cognition in brain aging. Stroke 2004; 35: 410-414.
120. Arvanitakis Z, Leurgans SE, Barnes LL, Bennett DA, Schneider JA. Microinfarct pathology, dementia, and cognitive systems. Stroke 2011; 42: 722-727.
121. Roman GC, Tatemichi TK, Erkinjuntti T etal. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250-260.
122. Mackenzie IR, Neumann M, Baborie A etal. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011; 122: 111-113.
123. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33-39.
124. Dickson DW, Braak H, Duda JE etal. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009; 8: 1150-1157.
125. Dickson DW. Required techniques and useful molecular markers in the neuropathologic diagnosis of neurodegenerative diseases. Acta Neuropathol 2005; 109: 14-24.
126. Hyman BT, Phelps CH, Beach TG etal. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012; 8: 1-13.
127. Dugger BN, Hentz JG, Adler CH etal. Clinicopathological outcomes of prospectively followed normal elderly brain bank volunteers. J Neuropathol Exp Neurol 2014; 73: 244-252.
128. Sabbagh MN, Sandhu SS, Farlow MR etal. Correlation of clinical features with argyrophilic grains at autopsy. Alzheimer Dis Assoc Disord 2009; 23: 229-233.
129. Jellinger KA, Attems J. Challenges of multimorbidity of the aging brain: a critical update. J Neural Transm 2014. [Epub ahead of print August 5].
130. Gusella JF, Macdonald ME. Huntington's disease. Semin Cell Biol 1995; 6: 21-28.
131. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31: 545-548.
132. Beach TG, Sue L, Scott S etal. Hippocampal sclerosis dementia with tauopathy. Brain Pathol 2003; 13: 263-278.
133. Meiser B, Dunn S. Psychological impact of genetic testing for Huntington's disease: an update of the literature. J Neurol Neurosurg Psychiatry 2000; 69: 574-578.
134. Bruni AC, Conidi ME, Bernardi L. Genetics in degenerative dementia: current status and applicability. Alzheimer Dis Assoc Disord 2014; 28: 199-205.
135. Le B. I. Genetics of frontotemporal lobar degeneration: an up-date and diagnosis algorithm. Rev Neurol (Paris) 2013; 169: 811-819.
136. Fong JC, Karydas AM, Goldman JS. Genetic counseling for FTD/ALS caused by the C9ORF72 hexanucleotide expansion. Alzheimers Res Ther 2012; 4: 27-36.
137. Perry EK, Perry RH, Tomlinson BE. The influence of agonal status on some neurochemical activities of postmortem human brain tissue. Neurosci Lett 1982; 29: 303-307.
138. Morrison-Bogorad M, Zimmerman AL, Pardue S. Heat-shock 70 messenger RNA levels in human brain: correlation with agonal fever. J Neurochem 1995; 64: 235-246.
139. Hardy JA, Wester P, Winblad B, Gezelius C, Bring G, Eriksson A. The patients dying after long terminal phase have acidotic brains; implications for biochemical measurements on autopsy tissue. J Neural Transm 1985; 61: 253-264.
140. Stan AD, Ghose S, Gao XM etal. Human postmortem tissue: what quality markers matter? Brain Res 2006; 1123: 1-11.
141. Yates CM, Butterworth J, Tennant MC, Gordon A. Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias. J Neurochem 1990; 55: 1624-1630.
142. Beach TG, Sue LI, Walker DG etal. The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank 2008; 9: 229-245.
143. Catts VS, Catts SV, Fernandez HR, Taylor JM, Coulson EJ, Lutze-Mann LH. A microarray study of post-mortem mRNA degradation in mouse brain tissue. Brain Res Mol Brain Res 2005; 138: 164-177.
144. Karkela JT. Critical evaluation of postmortem changes in human autopsy cisternal fluid. Enzymes, electrolytes, acid-base balance, glucose and glycolysis, free amino acids and ammonia. Correlation to total brain ischemia. J Forensic Sci 1993; 38: 603-616.
145. Botling J, Edlund K, Segersten U etal. Impact of thawing on RNA integrity and gene expression analysis in fresh frozen tissue. Diagn Mol Pathol 2009; 18: 44-52.
146. Nash DT, Fillit H. Cardiovascular disease risk factors and cognitive impairment. Am J Cardiol 2006; 97: 1262-1265.
147. Wolozin B, Bednar MM. Interventions for heart disease and their effects on Alzheimer's disease. Neurol Res 2006; 28: 630-636.
148. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005; 65: 545-551.
149. Kivipelto M, Helkala EL, Laakso MP etal. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447-1451.
150. Launer LJ, Ross GW, Petrovitch H etal. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging 2000; 21: 49-55.
151. Skoog I, Lernfelt B, Landahl S etal. 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-1145.
152. Astarita G, Jung KM, Berchtold NC etal. Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS ONE 2010; 5: e12538.
153. Bergmann C, Sano M. Cardiac risk factors and potential treatments in Alzheimer's disease. Neurol Res 2006; 28: 595-604.
154. Mielke MM, Zandi PP, Sjogren M etal. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 2005; 64: 1689-1695.
155. Rosano C, Newman AB. Cardiovascular disease and risk of Alzheimer's disease. Neurol Res 2006; 28: 612-620.
156. Sanderson M, Wang J, Davis DR, Lane MJ, Cornman CB, Fadden MK. Co-morbidity associated with dementia. Am J Alzheimers Dis Other Demen 2002; 17: 73-78.
157. Wolf-Klein GP, Siverstone FA, Brod MS etal. Are Alzheimer patients healthier? J Am Geriatr Soc 1988; 36: 219-224.
158. Irina A, Seppo H, Arto M, Paavo R, Sr, Hilkka S. beta-amyloid load is not influenced by the severity of cardiovascular disease in aged and demented patients. Stroke 1999; 30: 613-618.
159. Roher AE, Debbins JP, Malek-Ahmadi M etal. Cerebral blood flow in Alzheimer's disease. Vasc Health Risk Manag 2012; 8: 599-611.
160. Roher AE, Garami Z, Tyas SL etal. Transcranial doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer's disease. Alzheimers Dement 2011; 7: 445-455.
161. Roher AE, Esh C, Rahman A, Kokjohn TA, Beach TG. Atherosclerosis of cerebral arteries in Alzheimer disease. Stroke 2004; 35: 2623-2627.
162. Roher AE, Esh C, Kokjohn T, Sue L, Beach T. Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology 2005; 65: 974.
163. Roher AE, Esh C, Kokjohn TA etal. Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol 2003; 23: 2055-2062.
164. Roher AE, Tyas SL, Maarouf CL etal. Intracranial atherosclerosis as a contributing factor to Alzheimer's disease dementia. Alzheimers Dement 2011; 7: 436-444.
165. Beach TG, Maarouf CL, Brooks RG etal. Reduced clinical and postmortem measures of cardiac pathology in subjects with advanced Alzheimer's Disease. BMC Geriatr 2011; 11: 3.
166. Belohlavek M, Jiamsripong P, Calleja AM etal. Patients with Alzheimer disease have altered transmitral flow: echocardiographic analysis of the vortex formation time. J Ultrasound Med 2009; 28: 1493-1500.
167. Puddu P, Puddu GM, Bastagli L, Massarelli G, Muscari A. Coronary and cerebrovascular atherosclerosis: two aspects of the same disease or two different pathologies? Arch Gerontol Geriatr 1995; 20: 15-22.
168. Reed DM. The paradox of high risk of stroke in populations with low risk of coronary heart disease. Am J Epidemiol 1990; 131: 579-588.
169. Postiglione A, Nappi A, Brunetti A etal. Relative protection from cerebral atherosclerosis of young patients with homozygous familial hypercholesterolemia. Atherosclerosis 1991; 90: 23-30.
170. Kuramoto K, Ueda S, Matsushita S, Suzuki Y, Matsumoto Y, Iijima T. [Cholesterol, atherosclerosis and cerebro-cardiovascular complications in 3, 236 elderly autopsy cases]. Nippon Ronen Igakkai Zasshi 1991; 28: 188-193.
171. Konishi M, Komachi Y, Iso H etal. Secular trends in atherosclerosis of coronary arteries and basal cerebral arteries in Japan. The Akita pathology study. Arteriosclerosis 1990; 10: 535-540.
172. Tanaka K, Masuda J, Imamura T etal. A nation-wide study of atherosclerosis in infants, children and young adults in Japan. Atherosclerosis 1988; 72: 143-156.
173. Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology 2005; 64: 494-500.
174. Kosunen O, Talasniemi S, Lehtovirta M etal. Relation of coronary atherosclerosis and apolipoprotein E genotypes in Alzheimer patients. Stroke 1995; 26: 743-748.
175. Traykov L, Rigaud AS, Caputo L etal. Apolipoprotein E phenotypes in demented and cognitively impaired patients with and without cerebrovascular disease. Eur J Neurol 1999; 6: 415-421.
176. White H, Pieper C, Schmader K. The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc 1998; 46: 1223-1227.
177. White H, Pieper C, Schmader K, Fillenbaum G. Weight change in Alzheimer's disease. J Am Geriatr Soc 1996; 44: 265-272.
178. Wang PN, Yang CL, Lin KN, Chen WT, Chwang LC, Liu HC. Weight loss, nutritional status and physical activity in patients with Alzheimer's disease. A controlled study. J Neurol 2004; 251: 314-320.
179. Barrett-Connor E, Edelstein SL, Corey-Bloom J, Wiederholt WC. Weight loss precedes dementia in community-dwelling older adults. J Am Geriatr Soc 1996; 44: 1147-1152.
180. Gu Y, Scarmeas N, Cosentino S etal. Change in body mass index before and after Alzheimer's disease onset. Curr Alzheimer Res 2014; 11: 349-356.
181. Beach TG, Adler CH, Sue LI etal. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010; 119: 689-702.
182. Mu L, Sobotka S, Chen J etal. Altered pharyngeal muscles in Parkinson disease. J Neuropathol Exp Neurol 2012; 71: 520-530.
183. Mu L, Sobotka S, Chen J etal. Parkinson disease affects peripheral sensory nerves in the pharynx. J Neuropathol Exp Neurol 2013; 72: 614-623.
184. Mu L, Sobotka S, Chen J etal. Alpha-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson disease. J Neuropathol Exp Neurol 2013; 72: 119-129.
185. Annerino DM, Arshad S, Taylor GM, Adler CH, Beach TG, Greene JG. Parkinson's disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathol 2012; 124: 665-680.
186. Beach TG, Carew J, Serrano G etal. Phosphorylated alpha-synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects. Neurosci Lett 2014; 571: 34-38.
187. Adler CH, Beach TG, Hentz JG etal. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology 2014; 83: 406-412.
188. Beach TG. Alzheimer's disease and the "valley of death": not enough guidance from human brain tissue? J Alzheimers Dis 2013; 33: S219-S233.
189. Beach TG, Adler CH, Dugger BN etal. Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease. J Neuropathol Exp Neurol 2013; 72: 130-136.
190. Adler CH, Dugger BN, Hinni ML etal. Submandibular gland needle biopsy for the diagnosis of Parkinson disease. Neurology 2014; 82: 858-864.
191. Hewitt RE. Biobanking: the foundation of personalized medicine. Curr Opin Oncol 2011; 23: 112-119.
192. Massett HA, Atkinson NL, Weber D etal. Assessing the need for a standardized cancer HUman Biobank (caHUB): findings from a national survey with cancer researchers. J Natl Cancer Inst Monogr 2011; 2011: 8-15.
193. Myles R, Massett HA, Comey G, Atkinson N, Allsop D, Compton C. Stakeholder research on biospecimen needs and reactions to the development of a national cancer human biobank by the National Cancer Institute. J Natl Cancer Inst Monogr 2011; 2011: 16-23.
194. Rudloff U, Bhanot U, Gerald W etal. Biobanking of human pancreas cancer tissue: impact of ex-vivo procurement times on RNA quality. Ann Surg Oncol 2010; 17: 2229-2236.
195. Jia Z, Rahmatpanah FB, Chen X etal. Expression changes in the stroma of prostate cancer predict subsequent relapse. PLoS ONE 2012; 7: e41371.
196. Arora S, Korn RL, Lenkiewicz E etal. Clonal evolution of a case of treatment refractory maxillary sinus carcinoma. PLoS ONE 2012; 7: e45614.
197. Liu SV, Lenkiewicz E, Evers L etal. Genomic analysis and selected molecular pathways in rare cancers. Phys Biol 2012; 9: 065004.
198. Mikse OR, Blake DC, Jr, Jones NR etal. FOXO3 encodes a carcinogen-activated transcription factor frequently deleted in early-stage lung adenocarcinoma. Cancer Res 2010; 70: 6205-6215.
199. Hoglinger GU, Melhem NM, Dickson DW etal. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 2011; 43: 699-705.
200. Hamilton G, Killick R, Lambert JC etal. Functional and genetic analysis of haplotypic sequence variation at the nicastrin genomic locus. Neurobiol Aging 2012; 33: 1848.e1-13. doi: 10.1016/j.neurobiolaging.2012.02.005. Epub 2012 Mar 8.
201. Jun G, Vardarajan BN, Buros J etal. Comprehensive search for Alzheimer disease susceptibility loci in the APOE region. Arch Neurol 2012; 69: 1270-1279.
202. Miyashita A, Koike A, Jun G etal. SORL1 is genetically associated with late-onset Alzheimer's disease in Japanese, Koreans and Caucasians. PLoS ONE 2013; 8: e58618.
203. Reitz C, Jun G, Naj A etal. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E 4, and the risk of late-onset Alzheimer disease in African Americans. JAMA 2013; 309: 1483-1492.
204. Coppola G, Chinnathambi S, Lee JJ etal. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet 2012; 21: 3500-3512.
205. Rademakers R, Baker M, Gass J etal. Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. Lancet Neurol 2007; 6: 857-868.
206. Chen-Plotkin AS, Martinez-Lage M, Sleiman PM etal. Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. Arch Neurol 2011; 68: 488-497.
207. Van DV, Sleiman PM, Martinez-Lage M etal. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet 2010; 42: 234-239.
208. Naj AC, Jun G, Beecham GW etal. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011; 43: 436-441.
209. Lambert JC, Ibrahim-Verbaas CA, Harold D etal. Meta-analysis of 74, 046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013; 45: 1452-1458.
210. van Blitterswijk M, Mullen B, Heckman MG etal. Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiol Aging 2014; 35: 2421-2427.
211. van Blitterswijk M, Mullen B, Nicholson AM etal. TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol 2014; 127: 397-406.
212. van Blitterswijk M, Baker MC, Dejesus-Hernandez M etal. C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology 2013; 81: 1332-1341.
213. van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E etal. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol 2013; 12: 978-988.
214. Holton P, Ryten M, Nalls M etal. Initial assessment of the pathogenic mechanisms of the recently identified Alzheimer risk Loci. Ann Hum Genet 2013; 77: 85-105.
215. Jia Z, Wang Y, Sawyers A etal. Diagnosis of prostate cancer using differentially expressed genes in stroma. Cancer Res 2011; 71: 2476-2487.
216. Pio R, Jia Z, Baron VT, Mercola D. Early growth response 3 (Egr3) is highly over-expressed in non-relapsing prostate cancer but not in relapsing prostate cancer. PLoS ONE 2013; 8: e54096.
217. Whitcomb DC, LaRusch J, Krasinskas AM etal. Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis. Nat Genet 2012; 44: 1349-1354.
218. Dumitriu A, Latourelle JC, Hadzi TC etal. Gene expression profiles in Parkinson disease prefrontal cortex implicate FOXO1 and genes under its transcriptional regulation. PLoS Genet 2012; 8: e1002794.
219. Latourelle JC, Dumitriu A, Hadzi TC, Beach TG, Myers RH. Evaluation of Parkinson disease risk variants as expression-QTLs. PLoS ONE 2012; 7: e46199.
220. Zou F, Chai HS, Younkin CS etal. Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants. PLoS Genet 2012; 8: e1002707.
221. Zheng B, Liao Z, Locascio JJ etal. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2010; 2: 52ra73.
222. Berchtold NC, Sabbagh MN, Beach TG, Kim RC, Cribbs DH, Cotman CW. Brain gene expression patterns differentiate mild cognitive impairment from normal aged and Alzheimer's disease. Neurobiol Aging 2014; 35: 1961-1972.
223. Walker DG, Link J, Lue LF, Dalsing-Hernandez JE, Boyes BE. Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. J Leukoc Biol 2006; 79: 596-610.
224. Stamper C, Siegel A, Liang WS etal. Neuronal gene expression correlates of Parkinson's disease with dementia. Mov Disord 2008; 23: 1588-1595.
225. Liang WS, Reiman EM, Valla J etal. Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci U S A 2008; 105: 4441-4446.
226. Liang WS, Dunckley T, Beach TG etal. Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics 2008; 33: 240-256.
227. Liang WS, Dunckley T, Beach TG etal. Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics 2007; 28: 311-322.
228. Liang WS, Dunckley T, Beach TG etal. Neuronal gene expression in non-demented individuals with intermediate Alzheimer's Disease neuropathology. Neurobiol Aging 2008; 31: 549-566.
229. Parachikova A, Agadjanyan MG, Cribbs DH etal. Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol Aging 2007; 28: 1821-1833.
230. Weeraratna AT, Kalehua A, Deleon I etal. Alterations in immunological and neurological gene expression patterns in Alzheimer's disease tissues. Exp Cell Res 2007; 313: 450-461.
231. Dunckley T, Beach TG, Ramsey K etal. Gene expression correlates of neurofibrillary tangles in Alzheimer's disease. Neurobiol Aging 2006; 27: 1359-1371.
232. Reiman EM, Webster JA, Myers AJ etal. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 2007; 54: 713-720.
233. Coon KD, Valla J, Szelinger S etal. Quantitation of heteroplasmy of mtDNA sequence variants identified in a population of AD patients and controls by array-based resequencing. Mitochondrion 2006; 6: 194-210.
234. Webster JA, Myers AJ, Pearson JV etal. Sorl1 as an Alzheimer's disease predisposition gene? Neurodegener Dis 2007; 5: 60-64.
235. Webster JA, Gibbs JR, Clarke J etal. Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet 2009; 84: 445-458.
236. Finch N, Carrasquillo MM, Baker M etal. TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology 2011; 76: 467-474.
237. Burgos KL, Javaherian A, Bomprezzi R etal. Identification of extracellular miRNA in human cerebrospinal fluid by next-generation sequencing. RNA 2013; 19: 712-722.
238. Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, Rogers J. Epigenetic changes in Alzheimer's disease: decrements in DNA methylation. Neurobiol Aging 2010; 31: 2025-2037.
239. Chouliaras L, Mastroeni D, Delvaux E etal. Consistent decrease in global DNA methylation and hydroxymethylation in the hippocampus of Alzheimer's disease patients. Neurobiol Aging 2013; 34: 2091-2099.
240. Kellie JF, Higgs RE, Ryder JW etal. Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson's disease brain tissue by intact protein mass spectrometry. Sci Rep 2014; 4: 5797.
241. Beach TG, Sue LI, Walker DG etal. Striatal amyloid plaque density predicts Braak neurofibrillary stage and clinicopathological Alzheimer's disease: implications for amyloid imaging. J Alzheimers Dis 2012; 28: 869-876.
242. Dugger BN, Serrano GE, Sue LI etal. Presence of striatal amyloid plaques in Parkinson's disease dementia predicts concomitant Alzheimer's disease: usefulness for amyloid imaging. J Parkinsons Dis 2012; 2: 57-65.
243. Serrano GE, Sabbagh MN, Sue LI etal. Positive florbetapir PET amyloid imaging in a subject with frequent cortical neuritic plaques and frontotemporal lobar degeneration with TDP43-positive inclusions. J Alzheimers Dis 2014; 42: 813-821.
244. Lockhart A, Lamb JR, Osredkar T etal. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 2007; 130: 2607-2615.
245. Thompson PW, Ye L, Morgenstern JL etal. Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J Neurochem 2009; 109: 623-630.
246. Ye L, Velasco A, Fraser G etal. In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem 2008; 105: 1428-1437.
247. Kokjohn TA, Roher AE. Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial. CNS Neurol Disord Drug Targets 2009; 8: 88-97.
248. Maarouf CL, Daugs ID, Kokjohn TA etal. The biochemical aftermath of anti-amyloid immunotherapy. Mol Neurodegener 2010; 5: 39.
249. Patton RL, Kalback WM, Esh CL etal. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol 2006; 169: 1048-1063.
250. Roher AE, Cribbs DH, Kim RC etal. Bapineuzumab alters abeta composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy. PLoS ONE 2013; 8: e59735.
251. Roher AE, Maarouf CL, Daugs ID etal. Neuropathology and amyloid-beta spectrum in a bapineuzumab immunotherapy recipient. J Alzheimers Dis 2011; 24: 315-325.
252. Walker DG, Dalsing-Hernandez JE, Lue LF. Human postmortem brain-derived cerebrovascular smooth muscle cells express all genes of the classical complement pathway: a potential mechanism for vascular damage in cerebral amyloid angiopathy and Alzheimer's disease. Microvasc Res 2008; 75: 411-419.
253. Lue LF, Walker DG, Rogers J. Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol Aging 2001; 22: 945-956.
254. Lue LF, Rydel R, Brigham EF etal. Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro. Glia 2001; 35: 72-79.
255. Rogers J, Lue LF. Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease. Neurochem Int 2001; 39: 333-340.
256. Walker DG, Lue LF, Beach TG. Gene expression profiling of amyloid beta peptide-stimulated human post-mortem brain microglia. Neurobiol Aging 2001; 22: 957-966.
257. Li R, Shen Y, Yang LB, Lue LF, Finch C, Rogers J. Estrogen enhances uptake of amyloid beta-protein by microglia derived from the human cortex. J Neurochem 2000; 75: 1447-1454.
258. Hjelm BE, Salhia B, Kurdoglu A etal. In vitro-differentiated neural cell cultures progress towards donor-identical brain tissue. Hum Mol Genet 2013; 22: 3534-3546.
259. Hjelm BE, Rosenberg JB, Szelinger S etal. Induction of pluripotent stem cells from autopsy donor-derived somatic cells. Neurosci Lett 2011; 502: 219-224.
260. Truran S, Franco DA, Roher AE etal. Adipose and leptomeningeal arteriole endothelial dysfunction induced by beta-amyloid peptide: a practical human model to study Alzheimer's disease vasculopathy. J Neurosci Methods 2014; 235C: 123-129.
261. Prasad K, Beach TG, Hedreen J, Richfield EK. Critical role of truncated alpha-synuclein and aggregates in Parkinson's disease and incidental Lewy body disease. Brain Pathol 2012; 22: 811-825.
262. Lue LF, Walker DG, Adler CH etal. Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies. Brain Pathol 2012; 22: 745-756.
263. Walker DG, Lue LF, Adler CH etal. Changes in properties of serine 129 phosphorylated alpha-synuclein with progression of Lewy-type histopathology in human brains. Exp Neurol 2013; 240: 190-204.
264. Henderson-Smith A, Chow D, Meechoovet B etal. SMG1 identified as a regulator of Parkinson's disease-associated alpha-synuclein through siRNA screening. PLoS ONE 2013; 8: e77711.
265. Beach TG, Walker DG, Sue LI, Newell A, Adler CC, Joyce JN. Substantia nigra Marinesco bodies are associated with decreased striatal expression of dopaminergic markers. J Neuropathol Exp Neurol 2004; 63: 329-337.
266. Beach TG, Sue LI, Walker DG etal. Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits. Acta Neuropathol (Berl) 2007; 114: 419-424.
267. Joyce JN, Ryoo HL, Beach TB etal. Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors. Brain Res 2002; 955: 138-152.
268. Joyce JN, Ryoo H, Gurevich EV, Adler C, Beach T. Ventral striatal D(3) receptors and Parkinson's Disease. Parkinsonism Relat Disord 2001; 7: 225-230.
269. Adler CH, Hentz JG, Joyce JN, Beach T, Caviness JN. Motor impairment in normal aging, clinically possible Parkinson's disease, and clinically probable Parkinson's disease: longitudinal evaluation of a cohort of prospective brain donors. Parkinsonism Relat Disord 2002; 9: 103-110.
270. Beach TG, Sue LI, Scott S, Sparks DL. Neurofibrillary tangles are constant in aging human nucleus basalis. Alzheimers Rep 1998; 1: 375-380.
271. Beach TG, Kuo YM, Spiegel K etal. The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease. J Neuropathol Exp Neurol 2000; 59: 308-313.
272. Potter PE, Rauschkolb PK, Pandya Y etal. Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease. Acta Neuropathol 2011; 122: 49-60.
273. Walker DG, Dalsing-Hernandez JE, Campbell NA, Lue LF. Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation. Exp Neurol 2009; 215: 5-19.
274. Akiyama H, Barger S, Barnum S etal. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383-421.
275. Rogers J, Li R, Mastroeni D etal. Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes. Neurobiol Aging 2006; 27: 1733-1739.
276. Strohmeyer R, Shen Y, Rogers J. Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. Brain Res Mol Brain Res 2000; 81: 7-18.
277. Styren SD, Civin WH, Rogers J. Molecular, cellular, and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer's disease brain. Exp Neurol 1990; 110: 93-104.
278. Tooyama I, Sato H, Yasuhara O etal. Correlation of the expression level of C1q mRNA and the number of C1q-positive plaques in the Alzheimer Disease temporal cortex. analysis of C1q mrna and its protein using adjacent or nearby sections. Dement Geriatr Cogn Disord 2001; 12: 237-242.
279. Webster S, Lue LF, Brachova L etal. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging 1997; 18: 415-421.
280. Webster S, Bonnell B, Rogers J. Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide. Am J Pathol 1997; 150: 1531-1536.
281. Webster S, Bradt B, Rogers J, Cooper N. Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide. J Neurochem 1997; 69: 388-398.
282. Webster S, Rogers J. Relative efficacies of amyloid beta peptide (A beta) binding proteins in A beta aggregation. J Neurosci Res 1996; 46: 58-66.
283. Webster S, Glabe C, Rogers J. Multivalent binding of complement protein C1Q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation. Biochem Biophys Res Commun 1995; 217: 869-875.
284. Yermakova AV, Rollins J, Callahan LM, Rogers J, O'Banion MK. Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol 1999; 58: 1135-1146.
285. Lue LF, Brachova L, Civin WH, Rogers J. Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J Neuropathol Exp Neurol 1996; 55: 1083-1088.
286. Lue LF, Walker DG, Brachova L etal. Involvement of microglial receptor for advanced glycation endproducts (rage) in alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 2001; 171: 29-45.
287. Lue LF, Yan SD, Stern DM, Walker DG. Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease. Curr Drug Targets CNS Neurol Disord 2005; 4: 249-266.
288. Beach TG, Sue LI, Walker DG etal. Marked microglial reaction in normal aging human substantia nigra: correlation with extraneuronal neuromelanin pigment deposits. Acta Neuropathol 2007; 114: 419-424.
289. Nakahara H, Konishi Y, Beach TG, Yamada N, Makino S, Tooyama I. Infiltration of T lymphocytes and expression of icam-1 in the hippocampus of patients with hippocampal sclerosis. Acta Histochem Cytochem 2010; 43: 157-162.
290. Morimoto K, Horio J, Satoh H etal. Expression profiles of cytokines in the brains of Alzheimer's disease (AD) patients compared to the brains of non-demented patients with and without increasing AD pathology. J Alzheimers Dis 2011; 25: 59-76.
291. Tharp WG, Lee YH, Greene SM, Vincellete E, Beach TG, Pratley RE. Measurement of altered AbetaPP isoform expression in frontal cortex of patients with Alzheimer's disease by absolute quantification real-time PCR. J Alzheimers Dis 2012; 29: 449-457.
292. Konishi Y, Beach T, Sue LI, Hampel H, Lindholm K, Shen Y. The temporal localization of frame-shift ubiquitin-B and amyloid precursor protein, and complement proteins in the brain of non-demented control patients with increasing Alzheimer's disease pathology. Neurosci Lett 2003; 348: 46-50.
293. Caselli RJ, Walker D, Sue L, Sabbagh M, Beach T. Amyloid load in nondemented brains correlates with APOE e4. Neurosci Lett 2010; 473: 168-171.
294. Kane MD, Lipinski WJ, Callahan MJ etal. Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice. J Neurosci 2000; 20: 3606-3611.
295. Kuo YM, Emmerling MR, Woods AS, Cotter RJ, Roher AE. Isolation, chemical characterization, and quantitation of A beta 3- pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochem Biophys Res Commun 1997; 237: 188-191.
296. Kuo YM, Webster S, Emmerling MR, De Lima N, Roher AE. Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of Abeta peptides of Alzheimer's disease. Biochim Biophys Acta 1998; 1406: 291-298.
297. Kuo YM, Kokjohn TA, Kalback W etal. Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem Biophys Res Commun 2000; 268: 750-756.
298. Kuo YM, Kokjohn TA, Beach TG etal. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem 2001; 276: 12991-12998.
299. Kuo YM, Emmerling MR, Bisgaier CL etal. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. Biochem Biophys Res Commun 1998; 252: 711-715.
300. Lue LF, Kuo YM, Roher AE etal. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999; 155: 853-862.
301. Roher AE, Baudry J, Chaney MO, Kuo YM, Stine WB, Emmerling MR. Oligomerizaiton and fibril asssembly of the mayloid-beta protein. Biochim Biophys Acta 2000; 1502: 31-43.
302. Van Vickle GD, Esh CL, Kokjohn TA etal. Presenilin-1 280Glu-->Ala mutation alters C-terminal APP processing yielding longer abeta peptides: implications for Alzheimer's disease. Mol Med 2008; 14: 184-194.
303. Kokjohn TA, Van Vickle GD, Maarouf CL etal. Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets. Biochim Biophys Acta 2011; 1812: 1508-1514.
304. Kuo YM, Emmerling MR, Lampert HC etal. High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun 1999; 257: 787-791.
305. Maarouf CL, Daugs ID, Spina S etal. Histopathological and molecular heterogeneity among individuals with dementia associated with Presenilin mutations. Mol Neurodegener 2008; 3: 20.
306. Maarouf CL, Daugs ID, Kokjohn TA etal. Alzheimer's disease and non-demented high pathology control nonagenarians: comparing and contrasting the biochemistry of cognitively successful aging. PLoS ONE 2011; 6: e27291.
307. Roher AE, Kokjohn TA, Esh C etal. The human amyloid-beta precursor protein770 mutation V717F generates peptides longer than amyloid-beta-(40-42) and flocculent amyloid aggregates. J Biol Chem 2004; 279: 5829-5836.
308. Decourt B, Gonzales A, Beach TG etal. BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains. Curr Alzheimer Res 2013; 10: 309-315.
309. Han P, Tang Z, Yin J etal. Pituitary adenylate cyclase-activating polypeptide protects against beta-amyloid toxicity. Neurobiol Aging 2014; 35: 2064-2071.
310. Han P, Liang W, Baxter LC etal. Pituitary adenylate cyclase-activating polypeptide is reduced in Alzheimer disease. Neurology 2014; 82: 1724-1728.
311. Boeve BF, Silber MH, Ferman TJ etal. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med 2013; 14: 754-762.
312. Adler CH, Hentz JG, Shill HA etal. Probable RBD is increased in Parkinson's disease but not in essential tremor or restless legs syndrome. Parkinsonism Relat Disord 2011; 17: 456-458.
313. Adler CH, Shill HA, Beach TG. Essential tremor and Parkinson's disease: lack of a link. Mov Disord 2011; 26: 372-377.
314. Shill HA, Adler CH, Hentz JG. Purkinje cell loss in essential tremor. Mov Disord 2014; 29: 496-500.
315. Shill HA, Adler CH, Beach TG. Pathology in essential tremor. Parkinsonism Relat Disord 2012; 18 (Suppl 1): S135-S137.
316. Shill HA, Adler CH, Beach TG etal. Brain biochemistry in autopsied patients with essential tremor. Mov Disord 2012; 27: 113-117.
317. Shill HA, De LV, Samanta J, Stacy M. Motor learning in essential tremor. Mov Disord 2009; 24: 926-928.
318. Shneyder N, Adler CH, Hentz JG etal. Autonomic complaints in patients with restless legs syndrome. Sleep Med 2013; 14: 1413-1416.
319. Symanski C, Shill HA, Dugger B etal. Essential tremor is not associated with cerebellar Purkinje cell loss. Mov Disord 2014; 29: 496-500.
320. Shill HA, Adler CH, Sabbagh MN etal. Pathologic findings in prospectively ascertained essential tremor subjects. Neurology 2008; 70: 1452-1455.
321. Caviness JN, Adler CH, Hentz JG etal. Incidental Lewy body disease: electrophysiological findings suggesting pre-clinical Lewy body disorders. Clin Neurophysiol 2011; 122: 2426-2432.
322. Caviness JN, Sabbagh M, Connor D etal. Quantitative electroencephalography can distinguish between Parkinson's disease patient groups classified according to clinical cognitive dysfunction and neuropsychometric performance. Neurology 2006; 66 (5 Suppl 2): A210-A211.
323. Caviness JN, Adler CH, Beach TG, Wetjen KL, Caselli RJ. Small-amplitude cortical myoclonus in Parkinson's disease: physiology and clinical observations. Mov Disord 2002; 17: 657-662.
324. Caviness JN, Smith BE, Clarke SJ etal. Motor unit number estimates in idiopathic Parkinson's disease. Parkinsonism Relat Disord 2002; 8: 161-164.
325. Caviness JN, Lue LF, Beach TG etal. Parkinson's disease, cortical dysfunction, and alpha-synuclein. Mov Disord 2011; 26: 1436-1442.
326. Caviness JN, Adler CH, Sabbagh MN, Connor DJ, Hernandez JL, Lagerlund TD. Abnormal corticomuscular coherence is associated with the small amplitude cortical myoclonus in Parkinson's disease. Mov Disord 2003; 18: 1157-1162.
327. Caviness JN, Adler CH, Caselli RJ, Hernandez JL. Electrophysiology of the myoclonus in dementia with Lewy bodies. Neurology 2003; 60: 523-524.
328. Caviness JN, Hentz JG, Evidente VG etal. Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease. Parkinsonism Relat Disord 2007; 13: 348-354.
329. Caviness JN, Shill HA, Sabbagh MN, Evidente VG, Hernandez JL, Adler CH. Corticomuscular coherence is increased in the small postural tremor of Parkinson's disease. Mov Disord 2006; 21: 492-499.
330. Klassen BT, Hentz JG, Shill HA etal. Quantitative EEG as a predictive biomarker for Parkinson disease dementia. Neurology 2011; 77: 118-124.
331. Sabbagh MN, Lahti T, Connor DJ etal. Functional ability correlates with cognitive impairment in Parkinson's disease and Alzheimer's disease. Dement Geriatr Cogn Disord 2007; 24: 327-334.
332. Sabbagh MN, Cooper K, DeLange J etal. Functional, global and cognitive decline correlates to accumulation of Alzheimer's pathology in MCI and AD. Curr Alzheimer Res 2010; 7: 280-286.
333. Sabbagh MN, Silverberg N, Bircea S etal. Is the functional decline of Parkinson's disease similar to the functional decline of Alzheimer's disease? Parkinsonism Relat Disord 2005; 11: 311-315.
334. Adler CH. Mild cognitive impairment in Parkinson's disease. Parkinsonism Relat Disord 2009; 15 (Suppl 3): S81-S82.
335. Caviness JN, Driver-Dunckley E, Connor DJ etal. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007; 22: 1272-1277.
336. Sabbagh MN, Shah F, Reid RT etal. Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging. Arch Neurol 2006; 63: 1771-1776.
337. Adler CH, Connor DJ, Hentz JG etal. Incidental Lewy body disease: clinical comparison to a control cohort. Mov Disord 2010; 25: 642-646.
338. Caviness JN, Adler CH, Beach TG, Wetjen KL, Caselli RJ. Myoclonus in Lewy body disorders. Adv Neurol 2002; 89: 23-30.
339. Damian A, Adler CH, Hentz JG etal. Autonomic function, as self-reported on the SCOPA-autonomic questionnaire, is normal in essential tremor but not in Parkinson's disease. Parkinsonism Relat Disord 2012; 18: 1089-1093.
340. Okuda T, Shiotani S, Sakamoto N, Kobayashi T. Background and current status of postmortem imaging in Japan: short history of "Autopsy imaging (Ai)". Forensic Sci Int 2013; 225: 3-8.
341. Beach TG, Schneider JA, Sue LI etal. Theoretical impact of Florbetapir (18F) amyloid imaging on diagnosis of alzheimer dementia and detection of preclinical cortical amyloid. J Neuropathol Exp Neurol 2014; 73: 948-953.
342. Ikonomovic MD, Klunk WE, Abrahamson EE etal. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131: 1630-1645.
343. Leinonen V, Koivisto AM, Savolainen S etal. Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease. Ann Neurol 2010; 68: 446-453.
344. Rinne JO, Wong DF, Wolk DA etal. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid beta detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies. Acta Neuropathol 2012; 124: 833-845.
345. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69: 2197-2204.